Jason Coloma Sells 6,982 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 6,982 shares of the business’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $26.00, for a total transaction of $181,532.00. Following the sale, the chief executive officer directly owned 28,523 shares of the company’s stock, valued at approximately $741,598. This represents a 19.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Price Performance

Shares of NASDAQ:MAZE opened at $26.40 on Friday. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. Maze Therapeutics, Inc. has a fifty-two week low of $9.73 and a fifty-two week high of $53.65. The firm has a 50-day simple moving average of $29.21 and a 200 day simple moving average of $37.59. The company has a market cap of $1.46 billion, a PE ratio of -10.43 and a beta of 2.50.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The company had revenue of $20.00 million for the quarter. On average, sell-side analysts anticipate that Maze Therapeutics, Inc. will post -2.74 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. BTIG Research restated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, March 25th. Mizuho upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. Guggenheim upped their target price on shares of Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Finally, HC Wainwright upped their target price on shares of Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $66.00.

Institutional Trading of Maze Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Washington University boosted its holdings in shares of Maze Therapeutics by 33.3% in the fourth quarter. Washington University now owns 280,802 shares of the company’s stock valued at $11,634,000 after acquiring an additional 70,121 shares in the last quarter. Mass General Brigham Inc bought a new position in shares of Maze Therapeutics in the fourth quarter valued at approximately $9,943,000. ArrowMark Colorado Holdings LLC bought a new position in shares of Maze Therapeutics in the third quarter valued at approximately $14,135,000. Boothbay Fund Management LLC boosted its holdings in shares of Maze Therapeutics by 365.9% in the third quarter. Boothbay Fund Management LLC now owns 351,875 shares of the company’s stock valued at $9,124,000 after acquiring an additional 276,345 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Maze Therapeutics by 27.1% in the fourth quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock valued at $70,307,000 after acquiring an additional 362,060 shares in the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.